Telomir Pharmaceuticals’ FDA Milestone in Triple-Negative Breast CancerBusiness PenMay 7, 2026May 25, 2026 May 7, 2026May 25, 2026 [stock_market_widget type=”card” template=”basic2″ assets=”TELO” realtime=”true” api=”yahoo-finance”] Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has cleared one of the more nerve-wracking hurdles in the drug-development calendar: the U.S....
